Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of “Hold” by Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has earned an average rating of “Hold” from the six analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $3.2250.

A number of equities analysts have recently issued reports on LXRX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday. Wall Street Zen cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th.

Institutional Trading of Lexicon Pharmaceuticals

Hedge funds have recently modified their holdings of the company. CIBC Bancorp USA Inc. bought a new stake in Lexicon Pharmaceuticals during the 3rd quarter worth approximately $3,240,000. Millennium Management LLC boosted its stake in Lexicon Pharmaceuticals by 133.1% in the third quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock worth $5,171,000 after purchasing an additional 2,187,396 shares in the last quarter. AQR Capital Management LLC acquired a new position in Lexicon Pharmaceuticals in the first quarter worth $541,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Lexicon Pharmaceuticals during the third quarter worth $935,000. Finally, Vanguard Group Inc. increased its stake in shares of Lexicon Pharmaceuticals by 7.6% in the third quarter. Vanguard Group Inc. now owns 9,521,874 shares of the biopharmaceutical company’s stock valued at $12,855,000 after buying an additional 670,838 shares in the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Down 3.4%

LXRX opened at $1.70 on Monday. The company has a market capitalization of $617.78 million, a P/E ratio of -8.95 and a beta of 0.71. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63. The firm’s fifty day moving average price is $1.31 and its two-hundred day moving average price is $1.27. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $1.83.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The company had revenue of $14.18 million during the quarter, compared to the consensus estimate of $5.81 million. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. On average, analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.